Regarding toxicity, first-generation EGFR-TKIs showed diarrhea in 57%, skin rash in 48%, AST elevation in 25%, and interstitial lung disease in 2% of patients, while osimertinib showed milder toxicities (diarrhea 58%, skin rash 25%, AST elevation 9%, and interstitial lung disease 4%). The gene discussed is EGFR; the disease is exanthem.